Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.
(2013) In Medical Oncology 30(4). p.757-757- Abstract
- Protein kinase C (PKC) belongs to a family of ten serine/threonine protein kinases encoded by nine genes. This family of proteins plays critical roles in signal transduction which results in cell proliferation, survival, differentiation and apoptosis. Due to differential subcellular localization and tissue distribution, each member displays distinct signaling characteristics. In this review, we have summarized the roles of PKC family members in chronic lymphocytic leukemia (CLL). CLL is a heterogeneous hematological disorder with survival ranging from months to decades. PKC isoforms are differentially expressed in CLL and play critical roles in CLL pathogenesis. Thus, isoform-specific PKC inhibitors may be an attractive option for CLL... (More)
- Protein kinase C (PKC) belongs to a family of ten serine/threonine protein kinases encoded by nine genes. This family of proteins plays critical roles in signal transduction which results in cell proliferation, survival, differentiation and apoptosis. Due to differential subcellular localization and tissue distribution, each member displays distinct signaling characteristics. In this review, we have summarized the roles of PKC family members in chronic lymphocytic leukemia (CLL). CLL is a heterogeneous hematological disorder with survival ranging from months to decades. PKC isoforms are differentially expressed in CLL and play critical roles in CLL pathogenesis. Thus, isoform-specific PKC inhibitors may be an attractive option for CLL treatment. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4179969
- author
- Kazi, Julhash U. LU ; Kabir, Nuzhat N and Rönnstrand, Lars LU
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Medical Oncology
- volume
- 30
- issue
- 4
- pages
- 757 - 757
- publisher
- Humana Press
- external identifiers
-
- wos:000327858800006
- pmid:24174318
- scopus:84886445247
- pmid:24174318
- ISSN
- 1559-131X
- DOI
- 10.1007/s12032-013-0757-7
- language
- English
- LU publication?
- yes
- additional info
- The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Experimental Clinical Chemistry (013016010)
- id
- fc5015fa-1588-403c-a08b-a8902651b383 (old id 4179969)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/24174318?dopt=Abstract
- date added to LUP
- 2016-04-01 10:13:05
- date last changed
- 2022-04-27 19:49:11
@article{fc5015fa-1588-403c-a08b-a8902651b383, abstract = {{Protein kinase C (PKC) belongs to a family of ten serine/threonine protein kinases encoded by nine genes. This family of proteins plays critical roles in signal transduction which results in cell proliferation, survival, differentiation and apoptosis. Due to differential subcellular localization and tissue distribution, each member displays distinct signaling characteristics. In this review, we have summarized the roles of PKC family members in chronic lymphocytic leukemia (CLL). CLL is a heterogeneous hematological disorder with survival ranging from months to decades. PKC isoforms are differentially expressed in CLL and play critical roles in CLL pathogenesis. Thus, isoform-specific PKC inhibitors may be an attractive option for CLL treatment.}}, author = {{Kazi, Julhash U. and Kabir, Nuzhat N and Rönnstrand, Lars}}, issn = {{1559-131X}}, language = {{eng}}, number = {{4}}, pages = {{757--757}}, publisher = {{Humana Press}}, series = {{Medical Oncology}}, title = {{Protein kinase C (PKC) as a drug target in chronic lymphocytic leukemia.}}, url = {{https://lup.lub.lu.se/search/files/1659083/4497691.pdf}}, doi = {{10.1007/s12032-013-0757-7}}, volume = {{30}}, year = {{2013}}, }